The World Health Organization (WHO) has prequalified a biosimilar of version of rituximab, which is used to treat certain cancers and autoimmune diseases, created by Celltrion. This drug therapy is the second to achieve prequalification status under the prequalification pilot program since its inception in 2018. The program is meant to help ease the transition of the adoption of these drugs in nations with fewer resources, and is expected to cost about half the price of the original biologic. “Like generic medicines, biosimilars can be much less expensive versions of innovator biotherapeutics while keeping the same quality, safety and efficacy,” the WHO said.
Read more here.